James Foster
Associate
James Foster is an associate in the London office of Wilson Sonsini Goodrich & Rosati, where he works with companies and investors in the technology, life sciences, and green energy sectors. From start-ups to the world’s most valuable companies, James has advised clients on a wide range of corporate and commercial matters, including private M&A, fundraisings, joint ventures, technology commercialisation, and company law issues.
Experience
James Foster is an associate in the London office of Wilson Sonsini Goodrich & Rosati, where he works with companies and investors in the technology, life sciences, and green energy sectors. From start-ups to the world’s most valuable companies, James has advised clients on a wide range of corporate and commercial matters, including private M&A, fundraisings, joint ventures, technology commercialisation, and company law issues.
Education
- Postgraduate Diploma in Law (GDL) and Legal Practice Course (LPC), BPP University, London, United Kingdom, 2012
- B.Sc. (Hons), Business Management, King's College London, 2010
Admissions
- Solicitor, England and Wales
Credentials
Education
- Postgraduate Diploma in Law (GDL) and Legal Practice Course (LPC), BPP University, London, United Kingdom, 2012
- B.Sc. (Hons), Business Management, King's College London, 2010
Admissions
- Solicitor, England and Wales
Select Matters
James has advised:
- Chegg on its €385 million acquisition of Busuu
- Baylis Medical on the $1.75 billion sale of its cardiology business to Boston Scientific
- Uber on the sale and restructuring of its interests in various joint ventures with Yandex
- Contentsquare on its acquisition of Hotjar
- Learnosity, a Battery Ventures portfolio company, on its acquisition of Questionmark, an assessments, proctoring, and reporting solutions provider
- Bain & Company on its acquisition of Tech Economy, a technology consultancy
- Snyk on its acquisition of FossID, a developer of automated Software Composition Analysis tools based in Sweden
- Snyk on its acquisition of DeepCodeAG, a provider of real-time semantic code analysis based in Switzerland
- Snap on various undisclosed transactions
- Cornerstone OnDemand, Inc., a global leader in people development solutions, on the UK aspects of its $1.295 billion acquisition of Saba, a talent solution company
- Bavarian Nordic on its agreement to acquire the manufacturing and global rights to two commercial vaccines from GSK for €796 million
- Therachon, a clinical-stage biotechnology company focused on rare diseases, on its sale to Pfizer for up to $810 million
- Battery Ventures on its acquisition of Guardsquare, a security company focused on protecting complex mobile applications
- RenalytixAI, a developer of AI-enabled clinical diagnostics for kidney disease, on its £22.25 million initial public offering
- General Electric on its acquisition of the thermal, renewable and grid businesses of Alstom for €12.35 billion (IFLR European M&A deal of the year 2016)
- DMGT as 52% shareholder of Zoopla on its IPO, with a market capitalisation of £919 million
Matters
Select Matters
James has advised:
- Chegg on its €385 million acquisition of Busuu
- Baylis Medical on the $1.75 billion sale of its cardiology business to Boston Scientific
- Uber on the sale and restructuring of its interests in various joint ventures with Yandex
- Contentsquare on its acquisition of Hotjar
- Learnosity, a Battery Ventures portfolio company, on its acquisition of Questionmark, an assessments, proctoring, and reporting solutions provider
- Bain & Company on its acquisition of Tech Economy, a technology consultancy
- Snyk on its acquisition of FossID, a developer of automated Software Composition Analysis tools based in Sweden
- Snyk on its acquisition of DeepCodeAG, a provider of real-time semantic code analysis based in Switzerland
- Snap on various undisclosed transactions
- Cornerstone OnDemand, Inc., a global leader in people development solutions, on the UK aspects of its $1.295 billion acquisition of Saba, a talent solution company
- Bavarian Nordic on its agreement to acquire the manufacturing and global rights to two commercial vaccines from GSK for €796 million
- Therachon, a clinical-stage biotechnology company focused on rare diseases, on its sale to Pfizer for up to $810 million
- Battery Ventures on its acquisition of Guardsquare, a security company focused on protecting complex mobile applications
- RenalytixAI, a developer of AI-enabled clinical diagnostics for kidney disease, on its £22.25 million initial public offering
- General Electric on its acquisition of the thermal, renewable and grid businesses of Alstom for €12.35 billion (IFLR European M&A deal of the year 2016)
- DMGT as 52% shareholder of Zoopla on its IPO, with a market capitalisation of £919 million
Recent Insights
Client Advisories
Managing “Board”-dom: Transatlantic Companies and Non-Executive Directors
Directors can play a key role in the success of start-ups and scale-ups in both the UK and the U.S. However, differences between legal frameworks and governance norms, as well as the experience and approach applied by directors in different jurisdictions, mean that the role, expectations, and benefits that come with these appointments can vary quite significantly.
Learn More
Client Highlights
Wilson Sonsini Advises Recursion on Definitive Agreement with Exscientia
On August 8, 2024, Recursion and Exscientia announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.